Caring for Lesbians, Bisexual Women, Transgender, and Gender Nonconforming People

Gender-Affirming Hormone Therapy for Transgender Females

RANDOLPH, JOHN F. Jr MD

Author Information

Department of Obstetrics and Gynecology and Center for Reproductive Michigan Medicine, University of Michigan, Ann Arbor, Michigan

The authors declare that they have nothing to disclose.

Correspondence: John F. Randolph Jr, MD, Department of Obstetrics and Gynecology, University of Michigan, Center for Reproductive Michigan Medicine, 475 Market Place, Building 1, Suite B, Ann Arbor, MI. E-mail: [email protected]

Clinical Obstetrics and Gynecology 61(4):p 705-721, December 2018. | DOI: 10.1097/GRF.0000000000000396

Abstract

The provision of hormone therapy, both estrogens and antiandrogens, to adult transgender females is well within the scope of practice of the obstetrician gynecologist. The goal is to induce feminizing changes and suppress previously developed masculinization. Estrogens in sufficient doses will usually achieve both goals with augmentation by antiandrogens. The primary short-term risk of estrogens is thrombosis, but long-term risk in transgender females is unclear. Optimal care requires pretreatment education and assessment, individualized dosing, ongoing routine monitoring, and standard breast and prostate cancer screening.

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

Full Text Access for Subscribers:

Not a Subscriber?

Buy
Request Permissions

You can read the full text of this article if you:

Access through Ovid